CITIC Securities: China Vaccine Batch Releases Rose 14.1% YoY to 875 in Q1 2026
2026-06-23 00:48:40
A research note from CITIC Securities said China’s vaccine industry recorded 875 batch releases in the first quarter of 2026, up 14.1% year on year, driven mainly by sharp increases in releases of polio, measles-mumps-rubella (MMR) and hepatitis vaccines, according to 36Kr. On the R&D front, the note said several products or new indications were approved in Q1 2026, including Chengda Bio’s human diploid rabies vaccine, CanSino’s MCV4 meningococcal vaccine age-range expansion and its acellular pertussis combination vaccine, and Shenzhen Kangtai Biological Products’ quadrivalent split influenza vaccine. It added that multiple other vaccine candidates are in the marketing review stage.
Disclaimer:
1. The information provided does not constitute investment advice. Investors should make independent decisions and bear all risks themselves.
2. The copyright of this content belongs to the original author. The views expressed herein are solely those of the author and do not represent the stance or position of this website.
